肿瘤细胞治疗研究
ALL SOURCES
Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.
本研究建立了一种快速、符合 GMP 要求的方法，可直接从全血制造多功能的 CAR-T 细胞。本文概述的工作流程获得了强效、表型有利的 CAR-T 细胞产品，且未损害活力或细胞毒性功能。与标准 7 天方法相比，3 天方案导致与更干细胞样表型相关的基因表达，同时缩短了生产时间并降低了成本。该方法可为分散式 CAR-T 细胞生产提供一种实用替代方案，尤其适用于资源有限的环境。
Single-Cell Dissection Reveals Immune Dysregulation After CD5 or CD7-Directed Chimeric Antigen Receptor T-Cell Therapy.
Chimeric antigen receptor T-cell therapies related to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: Diagnosis, hig
CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma.
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.
Trogocytosis at the crossroad of cancer and immunity: mechanisms, implications and therapeutic perspectives.
Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia.
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.
作为一种具有巨大潜力和临床应用前景的抗肿瘤疗法，CAR-T 细胞疗法仍处于快速发展阶段。CAR-T 细胞相关领域在未来仍将是研究热点。
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE i
High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
